|
SORRY to be the party-pooper, but the article above applies only to IBC
that is,inflammatory breast cancer, not IDC infiltrating ductal breast cancer, which thevast majority of her2 neu+ breast cancer patients (and the majority of all breast cancer patients) have. Since this was the population studied, applying its results to a different population may be fraught with errors.
I am still awaiting the article I put everyone on the alert for--that regarding what markers her1,2,3,IGFR,etc are associated with lapatinib efficacy in ALL patients.
Hope it comes out soon!
Lani
|